BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37756479)

  • 21. Targeting nonsense-mediated cystic fibrosis: is it premature to stop now?
    O'Sullivan BP
    Lancet Respir Med; 2014 Jul; 2(7):509-11. PubMed ID: 24836206
    [No Abstract]   [Full Text] [Related]  

  • 22. Nonstop treatment of cystic fibrosis.
    Dietz HC; Hamosh A
    Nat Med; 1996 Jun; 2(6):608-9. PubMed ID: 8640540
    [No Abstract]   [Full Text] [Related]  

  • 23. Quest for cystic fibrosis pharmacotherapy.
    Joo NS
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):861-2. PubMed ID: 18714439
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug bests cystic-fibrosis mutation.
    Ledford H
    Nature; 2012 Feb; 482(7384):145. PubMed ID: 22318583
    [No Abstract]   [Full Text] [Related]  

  • 25. Cystic fibrosis foundation opens drug discovery lab.
    Trivedi BP
    Science; 2016 Sep; 353(6305):1194-5. PubMed ID: 27634505
    [No Abstract]   [Full Text] [Related]  

  • 26. Medical genetic test reporting for cystic fibrosis (deltaF508) and factor V Leiden in North American laboratories.
    Andersson HC; Krousel-Wood MA; Jackson KE; Rice J; Lubin IM
    Genet Med; 2002; 4(5):324-7. PubMed ID: 12394344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Italian and North American dietary intake after ivacaftor treatment for Cystic Fibrosis Gating Mutations.
    Sainath NN; Schall J; Bertolaso C; McAnlis C; Stallings VA
    J Cyst Fibros; 2019 Jan; 18(1):135-143. PubMed ID: 29983355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cystic fibrosis: molecular aspects and therapeutic prospects].
    Mazza P
    Boll Chim Farm; 1994 Jan; 133(1):35-8. PubMed ID: 8166964
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacological approaches to cystic fibrosis.
    Bandiera T; Galietta LJV
    Eur J Med Chem; 2021 Apr; 216():113240. PubMed ID: 33691259
    [No Abstract]   [Full Text] [Related]  

  • 31. Cystic fibrosis.
    Elborn JS
    Lancet; 2016 Nov; 388(10059):2519-2531. PubMed ID: 27140670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highlights from the 30th North American Cystic Fibrosis Conference, Orlando 2016.
    Shawcross A; Barry PJ
    Paediatr Respir Rev; 2018 Mar; 26():1-3. PubMed ID: 28400241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New pharmaceutical approaches to the treatment of cystic fibrosis.
    Delaney SJ; Wainwright BJ
    Nat Med; 1996 Apr; 2(4):392-3. PubMed ID: 8597941
    [No Abstract]   [Full Text] [Related]  

  • 34. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam AA; Higgins C; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD012040. PubMed ID: 28102546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel pharmacologic therapies for cystic fibrosis.
    Zeitlin PL
    J Clin Invest; 1999 Feb; 103(4):447-52. PubMed ID: 10021451
    [No Abstract]   [Full Text] [Related]  

  • 37. Mutation-specific cystic fibrosis treatments on verge of approval.
    Dolgin E
    Nat Med; 2011 Apr; 17(4):396-7. PubMed ID: 21475213
    [No Abstract]   [Full Text] [Related]  

  • 38. [Modifier genes and cystic fibrosis].
    Corvol H; Flamant C; Vallet C; Clement A; Brouard J
    Arch Pediatr; 2006 Jan; 13(1):57-63. PubMed ID: 16274977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
    McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
    Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excitement mounts for first disease-modifying cystic fibrosis drugs.
    Opar A
    Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.